To review the chemistry, pharmacokinetics, and clinical trials of two new classes of antihypertensive drugs, angiotensin II-receptor antagonists and renin inhibitors.
DATA SOURCES:
Primary literature on angiotensin II-receptor antagonists and renin inhibitors was identified through a comprehensive medical literature search from 1961 through 1993. This search included journal articles, abstracts, and reports of both animal and human research published in the English language. Indexing terms included renin-angiotensin aldosterone system, renin inhibitors, angiotensin II antagonists, DuP 753, losartan, MK954, A-64662, and Ro 42–5892.
STUDY SELECTIONS:
Emphasis was placed on clinical and pharmacokinetic studies in humans for drugs that are currently in Phase I—III research protocols in the US.
DATA EXTRACTION:
All available data from human studies were reviewed.
DATA SYNTHESIS:
Angiotensin II-receptor antagonists and renin inhibitors may be effective antihypertensives with few adverse effects noted in the small studies completed. Their potential advantage over angiotensin-converting enzyme (ACE) inhibitors includes a possible smaller adverse effect profile. In the past, the clinical utility of angiotensin II-receptor antagonists and renin inhibitors has been limited because of poor oral bioavailability, although newer agents are more readily bioavailable.
CONCLUSIONS:
Angiotensin II-receptor antagonists and renin inhibitors may be the next new classes of antihypertensives marketed. However, definitive conclusions about their roles in the management of hypertension are not possible until larger clinical trials assessing their efficacy and safety and comparing them with ACE inhibitors are completed.
Get full access to this article
View all access options for this article.
References
1.
BrunnerHRGavrasHWaeberBKershawGRTuriniGAVukovichRAOral angiotensin-converting enzyme inhibitor in long term treatment of hypertensive patients. Ann Intern Med1979; 90: 19–23.
2.
RaiaJJJrBaroneJAByerlyWGLacyCR. Angiotensin-converting enzyme inhibitors: a comparative review. DICP Ann Pharmacother1990; 24: 506–25.
3.
HednerTSamuelssonOLundeHLindholmLAndrénLWiholmBE. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ1992; 304: 941–6.
4.
SimonSRBlackHRMoserMBerlandWE. Cough and ACE inhibitors. Arch Intern Med1992; 152: 1698–700.
5.
MoriceAHBrownMJLowryRHigenbottamT. Angiotensin-converting enzyme and the cough reflex. Lancet1987; 14: 1116–8.
6.
LindgrenBRAnderssonRGG. Angiotensin converting enzyme inhibitors and their influence on inflammation, bronchial reactivity and cough. A research review. Med Toxicol Adverse Drug Exp1989; 4: 369–80.
7.
NolanCRSchrierRW. The kidney in hypertension. In: SchrierRW, ed. Renal and electrolyte disorders. Boston: Little, Brown and Company, 1992: 447–93.
BenetosAGavrasHStewartJMVavrekRJHatinoglouSGavrasI. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension1986; 8: 971–4.
13.
ConlinPRDluhyRGWilliamsGH. Disorders of the renin-angiotensin-aldosterone system. In: SchrierRW, ed. Renal and electrolyte disorders. Boston: Little, Brown and Company, 1992: 405–45.
14.
StreetenDHPAndersonGHJr. Angiotensin-receptor blocking drugs. In: DoyleAE, ed. Handbook of hypertension, clinical pharmacology of antihypertensive drugs. Amsterdam: Elsevier Science, 1984: 246–71.
15.
BrunnerHRGavrasHLaraghJHKeenanR. Angiotensin-II blockade in man by sar-ala-angiotensin II for understanding and treatment of high blood pressure. Lancet1973; 2: 1045–8.
16.
StreetenDHPAndersonGHFreibergJMDalakosTG. Use of an angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic” hypertension. N Engl J Med1975; 292: 657–62.
17.
HolckMBosseRFischliWGeroldHEscherE. An angiotensin II antagonist with strongly prolonged action. Biochem Biophys Res Commun1989; 3: 1350–6.
18.
DunciaJVChiuATCariniDJGregoryGBJohnsonALPriceWAThe discovery of potent nonpeptide angiotensin II receptor antagonists: a new class of potent antihypertensives. J Med Chem1990; 33: 1312–29.
19.
WongPCChiuATPriceWAThoolenMJMCCariniDJJohnsonALNonpeptide angiotensin II receptor antagonists. I. Pharmacological characterization of 2-n-butyl-4-chloro-l-(2-chlorobenzyl) imidazole-5-acetic acid, sodium salt (S-8307). J Pharmacol Exp Ther1988; 247: 1–7.
20.
WongPCPriceWAJrChiuATThoolenMJMCDunciaJVJohnsonALNonpeptide angiotensin II receptor antagonists. IV. EXP6155 and EXP6803. Hypertension1989; 13: 489–97.
21.
SieglPKSChangRSLMantloNBChakravartyPKOndeykaDLGreenleeWJIn vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther1992; 262: 139–44.
22.
OlinsGMCorpusVMMcMahonEGPalomoMASchuhJRBlehmDJIn vitro pharmacology of a nonpeptidic angiotensin II receptor antagonist, SC-51316. J Pharmacol Exp Ther1992; 261: 1037–43.
23.
WongPCPriceWAChiuATDunciaJVCariniDJWexlerRRNonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther1990; 252: 719–25.
24.
WongPCPriceWAChiuATDunciaJVCariniDJWexlerRRNonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther1990; 252: 726–32.
25.
WongPCPriceWAJrChiuATDunciaJVCariniDJWexlerRRHypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X. Hypertension1990; 15: 459–68.
26.
BunkenburgBSchnellCBaumHPCuminFWoodJM. Prolonged angiotensin II antagonism in spontaneously hypertensive rats. Hemodynamic and biochemical consequences. Hypertension1991; 18: 278–88.
27.
TofovicSPPongASJacksonEK. Effects of angiotensin subtype l and subtype 2 receptor antagonists in normotensive versus hypertensive rats. Hypertension1991; 18: 774–82.
28.
WongPCPriceWAChiuATDunciaJVCariniDJWexlerRRNonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther1992; 255: 211–7.
29.
ChristenYWaeberBNussbergerJLeeRJTimmermansPBMWMBrunnerHR. Dose-response relationships following oral administration of DuP 753 to normal humans. Am J Hypertens1991; 4 (suppl): 350s–3s.
30.
ChristenYWaeberBNussbergerJPorchetMBorlandRMLeeRJOral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II. Circulation1991; 83: 1333–42.
31.
MunafoAChristenYNussbergerJShumLYBorlandRMLeeRJDrug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther1992; 51: 513–21.
32.
LoMWShahinfarSFurtekCIRitterMShawCWGehrTPharmacokinetics of losartan (MK-954 or DuP 753) in patients with renal insufficiency (abstract). Clin Pharmacol Ther1993; 53: 160.
33.
ShawWKeaneWSicaDHalstensonCGehrTMarshallCSafety and antihypertensive effects of losartan (MK-954:DuP 753), an new angiotensin II receptor antagonist, in patients with hypertension and renal disease (abstract). Clin Pharmacol Ther1993; 53: 140.
WebbDJManhemPJBallSGInglisGLeckieBJLeverAFA study of the renin inhibitor H142 in man. J Hypertens1985; 3: 653–8.
36.
NussbergerJDelabaysAdeGasparoMCuminFWaeberBBrunnerHRHemodynamic and biochemical consequences of renin inhibition by infusion of CGP 38560A in normal volunteers. Hypertension1989; 13 (part 2): 948–53.
37.
JeunemaitreXMenardJNussbergerJGuyenneTTBrunnerHRCorvolP. Plasma angiotensins, renin, and blood pressure during acute renin inhibition by CGP 38560A in hypertensive patients. Hypertension1989; 2: 819–27.
38.
deGasparoMCuminFNussbergerJGuyenneTTWoodJMMenardJ. Pharmacological investigations of a new renin inhibitor in normal sodium-unrestricted volunteers. Br J Clin Pharmacol1989; 27: 587–96.
39.
DelabaysANussbergerJPorchetMWaeberBHoyosPBogerRHemodynamic and humoral effects of the new renin inhibitor enalkiren in normal humans. Hypertension1989; 13: 941–7.
40.
BursztynMGavrasITifftCPBauerJHMelbyJCGavrasH. Renin inhibition with A-64662: effect on blood pressure and hormonal response in man. J Hypertens1989; 7 (suppl): S306–7.
41.
BursztynMGavrasITifftCPLutherRBogerRGavrasH. Effects of a novel renin inhibitor in patients with essential hypertension. J Cardiovasc Pharmacol1990; 15: 493–500.
42.
BogerRSGlassmanHNCavanaughJHSchmitzPJLammJMoyseDProlonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension. Hypertension1990; 15: 835–40.
43.
GriffthsANNeutelJMGlassmanHNBogerRSWeberMALutherRR. The hypotensive effect of increasing doses of enalkiren, a dipeptide renin inhibitor, compared with enalaprilat in hypertensive patients. Br J Clin Pharmacol1990; 29: 614P–5P.
44.
AndersonPWDoYSSchambelanMHortonRBogerRSLutherRREffects of renin inhibition in systemic hypertension. Am J Cardiol1990; 66: 1342–7.
45.
WeberMANeutelJMEssingerIGlassmanHNBogerRSLutherR. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation1990; 81: 1768–74.
46.
NeutelJMLutherRRBogerRSWeberMA. Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat. Am Heart J1991; 122: 1094–100.
47.
GuptaSKGrannemanGRBogerRSHollenbergNKLutherRR. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a new renin inhibitor) I: single dose study. Drug Metab Dispos1992; 20: 821–5.
FischliWClozelJPAmraniKEWostlWNeidnartWStadlerHRo 42–5892 is a potent orally active renin inhibitor in primates. Hypertension1991; 18: 22–31.
50.
Van den MeirackerAHAdmiraalPJJManin'tVeldAJDerkxFHMRitsemavanEckHJMulderPProlonged blood pressure reduction by orally active renin inhibitor RO 42–5892 in essential hypertension. BMJ1990; 301: 205–10.
51.
MenardJGuyeneTTChatellierGKleinbloesemCHBernadetP. Renin release regulation during acute renin inhibition in normal volunteers. Hypertension1991; 18: 257–65.
52.
CamenzindENussbergerJJuilleratLMunafoAFischliWCoassoloPEffect of the renin response during renin inhibition: oral Ro 42–5892 in normal humans. J Cardiovasc Pharmacol1991; 18: 299–307.
53.
DoigJKMacFadyenRJMeredithPAFischliWReidJL. Neuro-hormonal and blood pressure responses to low-dose infusion of an orally active renin inhibitor, Ro 42–5892, in salt-replete men. J Cardiovasc Pharmacol1992; 20: 875–80.
54.
KiowskiWLinderLKleinbloesemCvan BrummelenPBuhlerFR. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation1992; 85: 1–8.
55.
NeubergGWKukinMLPennJMedinaNYushakMPackerM. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure. Am J Cardiol1991; 67: 63–6.
56.
HamperAL. Angiotensin converting enzyme (ACE) inhibitors and renal function. Drug Saf1991; 6: 361–70.
57.
VerburgKMKleinertHDChekalMAKadamJRCYoungGA. Renal hemodynamic and excretory responses to renin inhibition induced by A-64662. J Pharmacol Exp Ther1990; 252: 449–55.
58.
CorderoPFisherNDMooreTJGleasonRWilliamsGHHollenbergNK. Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans. Hypertension1991; 17: 510–6.
59.
NakashimaMUematsuTKosugeKKanamaruM. Pilot study of the uricosuric effect of DuP753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol1992; 42: 333–5.
